Researchers found that mutations in the PPP2R1A gene make ovarian clear cell carcinoma (OCCC) cells sensitive to ATR ...

Rakovina will present two abstracts at the meeting, the first: Discovery of novel PARP1-selective inhibitors for treatment of ...

Reports Q4 revenue $205,817 vs. $1,075 last year. “We made excellent progress across our pipeline in 2024, laying a strong foundation for the ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Rakovina Therapeutics Inc. has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in ...

Following a rigorous AI-driven selection process, the company shortlisted the most promising ATR inhibitor candidates for synthesis. The first batch of these compounds will now move into ...

Following a rigorous AI-driven selection process, the company shortlisted the most promising ATR inhibitor candidates for synthesis. The first batch of these compounds will now move into ...

(TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced today that the company has received the ...

After a thorough AI-guided selection process, promising ATR inhibitor candidates were shortlisted and have now been synthesized. These compounds are set to undergo preclinical testing in Rakovina ...

These forward-looking statements include, without limitation, statements, the expected timing of the presentation of data from the Phase 1b study of ATR-12, and statements about our clinical and ...